Medpace (NASDAQ:MEDP) Reaches New 1-Year High Following Strong Earnings

Key Points

• Medpace reported stronger-than-expected quarterly results: EPS was $4.84 versus the $4.44 consensus, while revenue rose 8.5% year over year to $716 million, slightly above estimates.
• The earnings beat sent shares to a new 52-week high of $684.52, although the stock’s consensus analyst rating remains “Hold” with an average price target of $607.73.
• Analyst optimism was supported by higher price targets, while Medpace’s board authorized a $1 billion share repurchase; separately, the CEO sold roughly $13.7 million of stock.

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) hit a new 52-week high during trading on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $684.52 and last traded at $658.70, with a volume of 120,986 shares trading hands. The stock had previously closed at $662.48.

The company reported $4.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.44 by $0.40. Medpace had a return on equity of 110.15% and a net margin of 17.67%. The business had revenue of $716.00 million for the quarter, compared to analysts' expectations of $714.47 million. During the same quarter last year, the firm earned $3.86 EPS. The business's revenue for the quarter was up 8.5% on a year-over-year basis.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Quarterly results exceeded expectations. Medpace earned $4.84 per share, above the $4.44–$4.45 analyst consensus and up from $3.86 a year earlier. Revenue increased 8.5% year over year to $716 million, narrowly exceeding the $714.47 million estimate. Medpace Holdings Profit Climbs in Q3
• Positive Sentiment: Margin expansion supported the earnings beat. Coverage highlighted improved profitability as a key driver of the 8.5% EPS beat, reinforcing Medpace’s earnings-growth story. The company reported a 17.67% net margin and 110.15% return on equity. Medpace Q3 2026 Earnings
• Positive Sentiment: Management provided an above-consensus 2026 earnings outlook. The guidance was described as higher than Wall Street expectations, which could support analyst estimate revisions and investor confidence. Medpace 2026 Earnings Guidance
• Positive Sentiment: The board authorized a $1 billion share repurchase. The buyback provides a significant capital-return commitment and may support per-share earnings over time, although the pace of repurchases remains uncertain. Medpace Gets $1 Billion Buyback Authorization
• Negative Sentiment: The initial market reaction was cautious. MEDP slipped despite the earnings beat and favorable outlook, suggesting investors may have viewed the report as broadly in line or remain concerned that revenue growth was not strong enough to justify the stock’s elevated valuation. Medpace Slips Despite Third-Quarter Beat

Wall Street Analyst Weigh In

MEDP has been the topic of several analyst reports. Weiss Ratings raised Medpace from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, October 8th. Mizuho upped their price objective on Medpace from $665.00 to $700.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 7th. Royal Bank Of Canada raised their price objective on shares of Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a research note on Friday, July 24th. Barclays lifted their target price on shares of Medpace from $600.00 to $625.00 and gave the company an "equal weight" rating in a report on Wednesday, October 7th. Finally, Truist Financial boosted their target price on shares of Medpace from $462.00 to $609.00 and gave the company a "hold" rating in a research note on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $607.73.

Insider Activity

In other Medpace news, CEO August Troendle sold 21,966 shares of the firm's stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total value of $13,739,074.02. Following the transaction, the chief executive officer owned 338,225 shares in the company, valued at approximately $211,549,590.75. This trade represents a 6.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold 336,140 shares of company stock valued at $208,008,328 over the last quarter. Insiders own 20.50% of the company's stock.

Hedge Funds Weigh In On Medpace

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in Medpace during the second quarter worth $1,323,047,000. Madison Asset Management LLC purchased a new stake in Medpace in the second quarter valued at $128,956,000. Bank of America Corp DE purchased a new stake in Medpace in the second quarter valued at $116,891,000. American Capital Management Inc. acquired a new position in shares of Medpace in the 2nd quarter valued at $111,329,000. Finally, Caisse de depot et placement du Quebec acquired a new position in shares of Medpace in the 2nd quarter valued at $80,979,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Stock Performance

The firm has a market cap of $18.37 billion, a price-to-earnings ratio of 38.61, a price-to-earnings-growth ratio of 2.78 and a beta of 1.18. The company has a 50 day moving average price of $608.40 and a 200 day moving average price of $535.64.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace's services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.